Rasmussen M, Fenger C, Kronborg O
Dept. of Surgery A, Odense University Hospital, Odense, Denmark.
Scand J Gastroenterol. 2003 Jan;38(1):114-8.
Flexible sigmoidoscopy (FS) has a higher degree of sensitivity for detecting colorectal neoplasia in the left side of the colon than Hemoccult (H-II). However, no randomized controlled trial has compared a single FS screening with a H-II screening program (annual or biennial) despite the well-documented mortality reduction from colorectal cancer (CRC) in the latter. The aim was to compare the diagnostic yield of colorectal neoplasia in two aged-matched groups from two different randomized screening trials; one group screened by a single FS+H-II, the other with biennial H-II over the course of 16 years.
24,465 persons invited to participate in the Funen biennial H-II screening program were compared with 4,460 similar persons invited to another Funen trial using a single FS+H-II.
Compliance in the biennial H-II program was 65.5% during the first screening round compared to 39.8% for FS+H-II. The cumulative number of persons with positive tests was 8.2% (positive H-II) in the biennial H-II program during 16 years and 20.3% (polyps > 3 mm in diameter seen at FS or positive H-II) for once-only FS+H-II. The diagnostic yield of CRC per 1,000 screened was 9.9 in the biennial H-II program and 6.6 after FS+H-II (6.5 and 2.7 per 1,000 invited). The yield of advanced adenomas (> or = 10 mm and/or villous structure and/or severe dysplasia) was 2.3% in the H-II program and 3.3% after FS+H-II among the screened persons, but this difference disappeared when persons invited, but not necessarily screened, were compared (1.5% versus 1.3%).
Screening with H-II in a biennial screening program during 16 years detected more CRCs than a single screening with FS+H-II and a similar number of advanced adenomas.
对于检测结肠左侧的结直肠肿瘤,可弯曲乙状结肠镜检查(FS)比隐血试验(H-II)具有更高的灵敏度。然而,尽管有充分证据表明后者可降低结直肠癌(CRC)死亡率,但尚无随机对照试验比较单次FS筛查与H-II筛查计划(每年或每两年一次)。目的是比较来自两项不同随机筛查试验的两个年龄匹配组中结直肠肿瘤的诊断率;一组通过单次FS+H-II进行筛查,另一组在16年期间每两年进行一次H-II筛查。
将受邀参加菲英岛每两年一次H-II筛查计划的24465人与受邀参加另一项菲英岛试验的4460名类似人员进行比较,后者采用单次FS+H-II。
在第一轮筛查中,每两年一次H-II计划的依从率为65.5%,而FS+H-II为39.8%。在16年期间,每两年一次H-II计划中检测呈阳性的累计人数为8.2%(H-II呈阳性),单次FS+H-II为20.3%(FS时发现直径>3mm的息肉或H-II呈阳性)。每1000名接受筛查者中CRC的诊断率,每两年一次H-II计划为9.9,FS+H-II后为6.6(每1000名受邀者中分别为6.5和2.7)。在接受筛查者中,进展期腺瘤(≥10mm和/或绒毛状结构和/或重度发育异常)的检出率在H-II计划中为2.3%,FS+H-II后为3.3%,但在比较受邀但不一定接受筛查的人员时,这种差异消失(分别为1.5%和1.3%)。
在16年期间每两年进行一次H-II筛查计划所检测出的CRC比单次FS+H-II筛查更多,且进展期腺瘤数量相近。